Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

131.43 +0.66 (+0.50%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
50 51 Next >
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break... 
Via TheNewswire.com
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
Longwood Healthcare Leaders to Bring Together Several Hundred Top Biotech and Pharmaceutical Leaders on Jan. 5-6, 2023
Longwood Fund, an early-stage life science venture firm, will convene several hundred top biotech and pharmaceutical leaders at its Pre-JPM Longwood Healthcare Leaders meeting, hosted virtually via... 
Via Newswire.com
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
These two rank among the 10 largest pharmaceutical companies on the planet. 
Via The Motley Fool
Novartis (NVS) Q3 2022 Earnings Call Transcript
NVS earnings call for the period ending September 30, 2022. 
Via The Motley Fool
3 Biotech Stocks Smart Investors Should Be Buying Up Now
These three biotech stocks could be among the best ways to play this uncertain market for those looking for long-term growth. 
Via InvestorPlace
Novartis' Malaria Treatment Candidate To Move Forward With Phase 3 Development Next Year
 
Via Benzinga
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Sales accelerated, again, in the third quarter. Here's what the company and analysts are watching. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose 
Via Benzinga
Novartis Offers Mixed Earnings Report As It Approaches A Key Spinoff
The spinoff will help Novartis become a "pure-play" innovative medicines giant, the company says. 
Via Investor's Business Daily
Novartis Clocks 4% Drop In Quarterly Sales, Once Again Perks Up Sandoz Earnings Outlook
 
Via Benzinga
TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO
Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Thoughts For Thursday: Correction Day!
The market remains agitated and it looks like it may be a long week from here to Thanksgiving. Yesterday the market remained chiefly in corrective mode, as it was down from the outset. 
Via Talk Markets
Novartis Mulls Disposing Its Non-Core Ophthalmology and Respiratory Units
Novartis AG (NYSE: NVS) is reportedly weighing divesting non-core assets as it seeks to raise money to invest in cutting-edge medicines, people familiar with the matter said. 
Via Benzinga
BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023
 
Via Benzinga
Should Income Investors Buy This High-Yielding Dividend Stock?
Novartis' product portfolio and pipeline bode well for its future. 
Via The Motley Fool
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Drug Repurposing Market to Eyewitness Huge Growth by 2027 : Allergan, Astellas Pharma, Biovista, NuMedii
Stay up-to-date with Drug Repurposing Market research offered by AMA. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Leading Data Analytics Company Vizlib Gains ISO 27001 Certification
About Vizlib Vizlib has revolutionised the way businesses of every size can get more from their data analytics investment into Qlik. With over 1,000 enterprise and public sector clients across the... 
Via PRUnderground
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
After FDA, European Agency Limits Use Of Certain JAK Inhibitors Amid Safety Concerns
 
Via Benzinga
3 High-Yielding Dividend Stocks That You Can Buy and Hold Forever
These stocks are all trading close to their 52-week lows. 
Via The Motley Fool
Cytokinetics CEO: Why It's OK Not Being An Overnight Success
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
Twitter Considers Crypto Wallet, Geopolitical Woes To Keep Tesla Shares Volatile, Juul Explores Possible Bailout: Top Stories Tuesday, Oct. 25
Benzinga 
Via Benzinga
Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?
Biosimilars are bringing down prescription drug costs without sacrificing quality. 
Via The Motley Fool
US Stock Futures Down; Big Tech Earnings In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Tuesday after recording gains in the previous session. The Dow Jones jumped by more than 400 points on Monday after all the... 
Via Benzinga
Recap: Novartis Q3 Earnings
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 25, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings Novartis beat estimated earnings by... 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.